Search results
Wall Street Analysts Believe Fate Therapeutics (FATE) Could Rally 172.49%: Here's is How to Trade
Zacks via Yahoo Finance· 1 year agoThe consensus price target hints at a 172.5% upside potential for Fate Therapeutics (FATE). While...
Fate Therapeutics Insiders US$207k Short Of Breakeven On Stock Purchase
Simply Wall St. via Yahoo Finance· 5 months agoInsiders who bought US$698.1k worth of Fate Therapeutics, Inc. (NASDAQ:FATE) stock in the last year...
Fate Therapeutics (FATE) Upgraded to Buy: Here's Why
Zacks via Yahoo Finance· 5 months agoFate Therapeutics (FATE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
While Fate Therapeutics (NASDAQ:FATE) shareholders have made 387% in 5 years, increasing losses...
Simply Wall St. via Yahoo Finance· 2 years agoFate Therapeutics, Inc. (NASDAQ:FATE) shareholders might understandably be very concerned that the...
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks via Yahoo Finance· 3 months agoFate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a...
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
Zacks via Yahoo Finance· 1 month agoFate Therapeutics’ FATE shares have surged 86.4% year to date compared with the industry’s growth of...
Fate Therapeutics, Inc.'s (NASDAQ:FATE) Low P/S No Reason For Excitement
Simply Wall St. via Yahoo Finance· 11 months agoFate Therapeutics, Inc.'s (NASDAQ:FATE) price-to-sales (or "P/S") ratio of 3.8x might make it look...
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 6 days agoFate Therapeutics (FATE) delivered earnings and revenue surprises of 0% and 140.63%, respectively,...
Shareholders in Fate Therapeutics (NASDAQ:FATE) are in the red if they invested a year ago
Simply Wall St. via Yahoo Finance· 1 year agoFate Therapeutics, Inc. (NASDAQ:FATE) shareholders should be happy to see the share price up 16% in...
FATE Incurs Narrower-Than-Expected Q1 Loss on Lower Expenses
Zacks via Yahoo Finance· 1 year agoFate Therapeutics FATE reported a loss of 19 cents per share in the first quarter of 2023, narrower...